JP2018529732A5 - - Google Patents

Download PDF

Info

Publication number
JP2018529732A5
JP2018529732A5 JP2018516738A JP2018516738A JP2018529732A5 JP 2018529732 A5 JP2018529732 A5 JP 2018529732A5 JP 2018516738 A JP2018516738 A JP 2018516738A JP 2018516738 A JP2018516738 A JP 2018516738A JP 2018529732 A5 JP2018529732 A5 JP 2018529732A5
Authority
JP
Japan
Prior art keywords
seq
sequence
strand comprises
rnai agent
sense strand
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2018516738A
Other languages
English (en)
Japanese (ja)
Other versions
JP6991966B2 (ja
JP2018529732A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2016/054729 external-priority patent/WO2017059223A2/en
Publication of JP2018529732A publication Critical patent/JP2018529732A/ja
Publication of JP2018529732A5 publication Critical patent/JP2018529732A5/ja
Application granted granted Critical
Publication of JP6991966B2 publication Critical patent/JP6991966B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2018516738A 2015-10-01 2016-09-30 Ｌｐａの遺伝子発現の阻害のための組成物及び方法 Active JP6991966B2 (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201562235816P 2015-10-01 2015-10-01
US62/235,816 2015-10-01
US201662346304P 2016-06-06 2016-06-06
US62/346,304 2016-06-06
US201662383221P 2016-09-02 2016-09-02
US62/383,221 2016-09-02
PCT/US2016/054729 WO2017059223A2 (en) 2015-10-01 2016-09-30 Compositions and methods for inhibiting gene expression of lpa

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2021039949A Division JP7116212B2 (ja) 2015-10-01 2021-03-12 Ｌｐａの遺伝子発現の阻害のための組成物及び方法

Publications (3)

Publication Number Publication Date
JP2018529732A JP2018529732A (ja) 2018-10-11
JP2018529732A5 true JP2018529732A5 (enExample) 2019-11-07
JP6991966B2 JP6991966B2 (ja) 2022-02-03

Family

ID=58424351

Family Applications (5)

Application Number Title Priority Date Filing Date
JP2018516738A Active JP6991966B2 (ja) 2015-10-01 2016-09-30 Ｌｐａの遺伝子発現の阻害のための組成物及び方法
JP2021039949A Active JP7116212B2 (ja) 2015-10-01 2021-03-12 Ｌｐａの遺伝子発現の阻害のための組成物及び方法
JP2022096415A Active JP7442574B2 (ja) 2015-10-01 2022-06-15 Ｌｐａの遺伝子発現の阻害のための組成物及び方法
JP2023199857A Withdrawn JP2024009262A (ja) 2015-10-01 2023-11-27 Ｌｐａの遺伝子発現の阻害のための組成物及び方法
JP2025179509A Pending JP2026040461A (ja) 2015-10-01 2025-10-24 Ｌｐａの遺伝子発現の阻害のための組成物及び方法

Family Applications After (4)

Application Number Title Priority Date Filing Date
JP2021039949A Active JP7116212B2 (ja) 2015-10-01 2021-03-12 Ｌｐａの遺伝子発現の阻害のための組成物及び方法
JP2022096415A Active JP7442574B2 (ja) 2015-10-01 2022-06-15 Ｌｐａの遺伝子発現の阻害のための組成物及び方法
JP2023199857A Withdrawn JP2024009262A (ja) 2015-10-01 2023-11-27 Ｌｐａの遺伝子発現の阻害のための組成物及び方法
JP2025179509A Pending JP2026040461A (ja) 2015-10-01 2025-10-24 Ｌｐａの遺伝子発現の阻害のための組成物及び方法

Country Status (36)

Country Link
US (4) US9932586B2 (enExample)
EP (2) EP3356529B1 (enExample)
JP (5) JP6991966B2 (enExample)
KR (1) KR102728481B1 (enExample)
CN (1) CN108368506A (enExample)
AU (3) AU2016331084B2 (enExample)
CA (1) CA3000397A1 (enExample)
CL (1) CL2018000803A1 (enExample)
CO (1) CO2018003678A2 (enExample)
CR (1) CR20180231A (enExample)
CY (1) CY1125263T1 (enExample)
DK (1) DK3356529T3 (enExample)
EA (1) EA038478B1 (enExample)
ES (1) ES2896298T3 (enExample)
HR (1) HRP20211410T1 (enExample)
HU (1) HUE055942T2 (enExample)
IL (3) IL300438A (enExample)
JO (2) JOP20210043A1 (enExample)
LT (1) LT3356529T (enExample)
MA (1) MA43347B1 (enExample)
MX (2) MX2018003833A (enExample)
MY (1) MY195796A (enExample)
PE (1) PE20181139A1 (enExample)
PH (1) PH12018500713A1 (enExample)
PL (1) PL3356529T3 (enExample)
PT (1) PT3356529T (enExample)
RS (1) RS62523B1 (enExample)
SG (1) SG10202008530TA (enExample)
SI (1) SI3356529T1 (enExample)
SM (1) SMT202100622T1 (enExample)
TN (1) TN2018000094A1 (enExample)
TW (3) TWI836693B (enExample)
UA (1) UA121998C2 (enExample)
UY (1) UY36926A (enExample)
WO (1) WO2017059223A2 (enExample)
ZA (1) ZA202106265B (enExample)

Families Citing this family (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7718133B2 (en) 2003-10-09 2010-05-18 3M Innovative Properties Company Multilayer processing devices and methods
MX2018009854A (es) * 2016-03-07 2018-11-09 Arrowhead Pharmaceuticals Inc Ligandos dirigidos para compuestos terapeuticos.
CN116832169A (zh) * 2016-09-02 2023-10-03 箭头药业股份有限公司 靶向配体
RS63836B1 (sr) 2017-04-05 2023-01-31 Silence Therapeutics Gmbh Proizvodi i sastavi
KR20200024793A (ko) * 2017-07-06 2020-03-09 애로우헤드 파마슈티컬스 인코포레이티드 알파-ENaC의 발현을 억제하기 위한 RNAi 작용제 및 사용 방법
JOP20200054A1 (ar) * 2017-09-11 2020-03-10 Arrowhead Pharmaceuticals Inc عوامل RNAi وتركيبات لتثبيط تعبير صَميمُ البروتينِ الشَّحْمِيّ C-III (APOC3)
AU2018331383B2 (en) * 2017-09-14 2024-12-05 Arrowhead Pharmaceuticals, Inc. RNAi agents and compositions for inhibiting expression of angiopoietin-like 3 (ANGPTL3), and methods of use
CN111655268B (zh) 2017-10-04 2024-03-26 艾维迪提生物科学公司 核酸-多肽组合物及其用途
WO2019079294A1 (en) * 2017-10-17 2019-04-25 Arrowhead Pharmaceuticals, Inc. RNAI-BASED AGENTS AND COMPOSITIONS FOR INHIBITING ASIALOGLYCOPROTEIN RECEPTOR 1 RECEPTOR 1
IL274503B2 (en) * 2017-11-13 2024-10-01 Silence Therapeutics Gmbh Nucleic acids for inhibiting expression of lpa in a cell
EP3483270A1 (en) * 2017-11-13 2019-05-15 Silence Therapeutics GmbH Products and compositions
CA3109553A1 (en) * 2018-09-19 2020-03-26 Arrowhead Pharmaceuticals, Inc. Rnai agents for inhibiting expression of 17beta-hsd type 13 (hsd17b13), compositions thereof, and methods of use
JP7245328B2 (ja) * 2018-11-13 2023-03-23 サイレンス・セラピューティクス・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング 細胞におけるｌｐａの発現を抑制するための核酸
US11578090B2 (en) * 2019-06-06 2023-02-14 Avidity Biosciences, Inc. Nucleic acid-polypeptide compositions and uses thereof
EP3983077A4 (en) * 2019-06-17 2023-12-20 Alnylam Pharmaceuticals, Inc. DELIVERY OF OLIGONUCLEOTIDES TO THE STRIATUM
CN112442499B (zh) * 2019-08-30 2026-03-10 恩康药业科技（广州）有限公司 一种抑制MCM7的siRNA、组合物及其应用
US20230078200A1 (en) * 2019-12-09 2023-03-16 Amgen Inc. RNAi CONSTRUCTS AND METHODS FOR INHIBITING LPA EXPRESSION
AU2021244329A1 (en) * 2020-03-23 2022-09-29 Amgen Inc. Monoclonal antibodies to chemically-modified nucleic acids and uses thereof
JP7476422B2 (ja) 2020-08-05 2024-04-30 ディセルナ ファーマシューティカルズ インコーポレイテッド Ｌｐａ発現を阻害するための組成物及び方法
US20240035029A1 (en) * 2020-10-16 2024-02-01 Sanofi Rna compositions and methods for inhibiting lipoprotein(a)
MX2023005198A (es) * 2020-11-05 2023-05-16 Amgen Inc Metodos para tratar la enfermedad cardiovascular aterosclerotica con constructos de iarn dirigidos a lpa.
WO2022121959A1 (zh) * 2020-12-09 2022-06-16 纳肽得有限公司 siRNA分子及其在治疗冠状动脉疾病中的应用
EP4237561A1 (en) 2020-12-23 2023-09-06 Argonaute Rna Limited Treatment of cardiovascular disease
JP2024523237A (ja) 2021-06-18 2024-06-28 ホンジーン バイオテック コーポレイション 官能化されたｎ－アセチルガラクトサミンヌクレオシド
EP4396193A4 (en) 2021-08-30 2025-07-02 Hongene Biotech Corp FUNCTIONALIZED N-ACETYLGALACTOSAMINE ANALOGUES
JP2024531728A (ja) 2021-09-14 2024-08-29 アルゴノート アールエヌエー リミテッド 心血管疾患の処置
AU2022348141A1 (en) * 2021-09-18 2024-04-04 Chengdu Xinzhenghe Pharmaceutical Technology Co. Ltd Lpa inhibitor and use thereof
MX2024005862A (es) 2021-11-16 2024-07-10 Shanghai Argo Biopharmaceutical Co Ltd Composiciones y metodos para inhibir la expresion de la proteina angiotensinogeno (agt).
EP4448540A1 (en) 2021-12-15 2024-10-23 Hongene Biotech Corporation Functionalized n-acetylgalactosamine analogs
EP4450624A4 (en) * 2021-12-16 2025-03-26 Tuojie Biotech (Shanghai) Co., Ltd. LPA-TARGETTING SIRNA AND CONJUGATE
CN114703184B (zh) * 2022-03-11 2024-06-18 厦门甘宝利生物医药有限公司 Lpa抑制剂及其用途
CN119698469A (zh) * 2022-08-11 2025-03-25 益杰立科(上海)生物科技有限公司 一种表观编辑靶点的方法及用途
CN115851723B (zh) * 2022-10-24 2023-10-03 厦门甘宝利生物医药有限公司 一种抑制lpa基因表达的rna抑制剂及其应用
WO2024118503A1 (en) 2022-11-28 2024-06-06 Hongene Biotech Corporation Functionalized n-acetylgalactosamine analogs
JP2026502533A (ja) * 2023-01-13 2026-01-23 イーライ リリー アンド カンパニー 治療用オリゴヌクレオチド含有医薬組成物及びそれを用いる投与レジメン
WO2024210530A1 (en) * 2023-04-03 2024-10-10 Olix Pharmaceuticals, Inc. RNAi AGENTS TARGETING LPA GENE AND USE THEREOF
CN121127587A (zh) * 2023-04-24 2025-12-12 上海京新生物医药有限公司 用于抑制LPA表达的RNAi剂及其应用
EP4714939A1 (en) 2023-05-19 2026-03-25 Shenzhen Salubris Pharmaceuticals Co., Ltd. Sulfonamide compound, preparation method therefor, and pharmaceutical use thereof
CN119343449A (zh) * 2023-05-24 2025-01-21 云合智药（苏州）生物科技有限公司 用于抑制angptl3表达的rnai剂及其应用
AU2024280186A1 (en) 2023-05-31 2025-12-04 Tuojie Biotech (Shanghai) Co., Ltd. Dsrna targeting lpa and use thereof
KR20260034076A (ko) * 2023-05-31 2026-03-10 애로우헤드 파마슈티컬스 인코포레이티드 다량체성 RNAi 작용제 접합체를 위한 간 전달 플랫폼 및 그의 사용 방법
DE102023115075A1 (de) * 2023-06-07 2024-12-12 B.Braun Avitum Ag Schlauchrollenpumpe
WO2025064821A2 (en) 2023-09-21 2025-03-27 Ionis Pharmaceuticals, Inc. Compounds and methods for inhibiting lpa
WO2025082058A1 (zh) * 2023-10-16 2025-04-24 润佳(上海)医药技术有限公司 一种抑制LPA基因表达的dsRNA及其用途
CN120344664A (zh) * 2023-10-27 2025-07-18 北京安龙生物医药有限公司 靶向脂蛋白a的寡核苷酸及其用途
TW202540420A (zh) * 2023-11-15 2025-10-16 大陸商北京加科瑞康醫藥科技有限公司 用於抑制LPA的基因表現的siRNA，含其的組合物及其用途
CN120020252A (zh) * 2023-11-17 2025-05-20 纳肽得(青岛)生物医药有限公司 抑制LPA表达的siRNA及其用途
CN120098993A (zh) * 2023-12-05 2025-06-06 广东东阳光药业股份有限公司 一种新型的双链siRNA、其缀合物及其用途
CN120485189B (zh) * 2025-07-16 2025-10-17 北京悦康科创医药科技股份有限公司 靶向调控LPA基因表达的siRNA及其用途

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL9201440A (nl) 1992-08-11 1994-03-01 Univ Leiden Triantennaire clusterglycosiden, hun bereiding en toepassing.
US5599706A (en) 1994-09-23 1997-02-04 Stinchcomb; Dan T. Ribozymes targeted to apo(a) mRNA
WO2000053722A2 (en) 1999-03-10 2000-09-14 Phogen Limited Delivery of nucleic acids and proteins to cells
KR100909681B1 (ko) * 2000-12-01 2009-07-29 막스-플랑크-게젤샤프트 츄어 푀르더룽 데어 비쎈샤프텐 에.파우. Ｒｎａ 간섭을 매개하는 작은 ｒｎａ 분자
US7227014B2 (en) 2001-08-07 2007-06-05 Isis Pharmaceuticals, Inc. Antisense modulation of apolipoprotein (a) expression
US7259150B2 (en) 2001-08-07 2007-08-21 Isis Pharmaceuticals, Inc. Modulation of apolipoprotein (a) expression
EP1613348B1 (en) 2003-03-12 2010-06-23 The Arizona Board of Regents on Behalf of the University of Arizona Methods for modulating angiogenesis with apelin compositions
US8084599B2 (en) 2004-03-15 2011-12-27 City Of Hope Methods and compositions for the specific inhibition of gene expression by double-stranded RNA
CN101500548A (zh) * 2006-08-18 2009-08-05 弗·哈夫曼-拉罗切有限公司 用于体内递送多核苷酸的多缀合物
CN102325534B (zh) 2008-12-18 2016-02-17 戴瑟纳制药公司 延长的dicer酶底物和特异性抑制基因表达的方法
US20100249214A1 (en) 2009-02-11 2010-09-30 Dicerna Pharmaceuticals Multiplex dicer substrate rna interference molecules having joining sequences
SG183374A1 (en) 2010-02-24 2012-09-27 Arrowhead Res Corp Compositions for targeted delivery of sirna
US8865675B2 (en) * 2010-05-12 2014-10-21 Protiva Biotherapeutics, Inc. Compositions and methods for silencing apolipoprotein B
US8501930B2 (en) 2010-12-17 2013-08-06 Arrowhead Madison Inc. Peptide-based in vivo siRNA delivery system
CA2816155C (en) * 2010-12-17 2020-10-27 Arrowhead Research Corporation Galactose cluster-pharmacokinetic modulator targeting moiety for sirna
SG189942A1 (en) 2010-12-29 2013-06-28 Arrowhead Res Corp In vivo polynucleotide delivery conjugates having enzyme sensitive linkages
HK1199736A1 (en) 2011-08-26 2015-07-17 箭头研究公司 Poly(vinyl ester) polymers for in vivo nucleic acid delivery
WO2013075035A1 (en) * 2011-11-18 2013-05-23 Alnylam Pharmaceuticals Rnai agents, compositions and methods of use thereof for treating transthyretin (ttr) associated diseases
WO2013158141A1 (en) 2012-04-18 2013-10-24 Arrowhead Research Corporation Poly(acrylate) polymers for in vivo nucleic acid delivery
WO2013177468A2 (en) * 2012-05-24 2013-11-28 Isis Pharmaceuticals, Inc. Methods and compositions for modulating apolipoprotein(a) expression
WO2014134483A2 (en) * 2013-02-28 2014-09-04 Immunogen, Inc. Conjugates comprising cell-binding agents and cytotoxic agents
PE20152002A1 (es) * 2013-05-01 2016-01-21 Isis Pharmaceuticals Inc Composiciones y metodos para modular la expresion de ttr y vhb
US20160272970A1 (en) 2015-03-17 2016-09-22 Arrowhead Madison Inc. RNA Interference Agents
WO2016196239A1 (en) 2015-05-29 2016-12-08 Arrowhead Pharmaceuticals, Inc. Compositions and methods for inhibiting gene expression of hif2alpha
PL3329002T3 (pl) * 2015-07-31 2021-04-19 Alnylam Pharmaceuticals, Inc. Kompozycje irna transtyretyny (ttr) i sposoby ich zastosowania do leczenia lub zapobiegania chorobom związanym z ttr
MX2018009854A (es) 2016-03-07 2018-11-09 Arrowhead Pharmaceuticals Inc Ligandos dirigidos para compuestos terapeuticos.

Similar Documents

Publication Publication Date Title
JP2018529732A5 (enExample)
TWI880645B (zh) 抑制lpa之基因表現之組合物及方法
JP6752151B2 (ja) 遺伝子サイレンシングにおいて低下したｏｆｆ−ｔａｒｇｅｔ効果を有するｕｎａオリゴマー
Vidal et al. Making sense of antisense
JP2020533334A5 (enExample)
JP2018536689A5 (enExample)
TW201922264A (zh) 用於抑制類血管生成素蛋白-3(ANGPTL3)表現的RNAi藥劑及組合物及使用方法
JP2020530442A5 (enExample)
CN108136206A (zh) 抗乙型肝炎病毒的组合物和药剂及其用途
CN108064313A (zh) 用于抑制因子xii的基因表达的组合物和方法
JP2018516091A5 (enExample)
JP2016522674A5 (enExample)
JP2016502858A5 (enExample)
IL316808A (en) Modified double-stranded RNA materials and their uses
JP2017525705A5 (enExample)
JP2017532038A5 (enExample)
JP2016528258A (ja) 非コードｒｎａを形成するヘテロクロマチン
JP7697889B2 (ja) アルファ－１アンチトリプシン欠乏症（ａａｔｄ）の治療法
KR20200131287A (ko) 마이크로-rna 22의 억제제
AU2016219052A1 (en) Compositions and methods for modulating RNA
JP2023506546A (ja) Ｂ型肝炎ウイルス感染症を処置するためのｓｅｐｔ９阻害剤の使用
KR101783444B1 (ko) miR-33-5p 를 이용한 뇌신경세포 보호 물질 스크리닝 방법
JP2018512140A (ja) 治療上のｕｎａオリゴマーおよびその使用
JPWO2021126734A5 (enExample)
JP2023506547A (ja) Ｂ型肝炎ウイルス感染を処置するためのｃｏｐｓ３阻害剤の使用